ARWR Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi; TPIV Announces Phase II Clinical Trials With VGTI Florida
November 19, 2014 at 03:29 AM EST
ARWR today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate.TPIV. is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida.